A non­prof­it group’s Cha­gas drug beat out Mar­tin Shkre­li's old ri­val to FDA OK, valu­able PRV

The FDA has ap­proved a new drug for Cha­gas dis­ease, but one of Mar­tin Shkre­li’s for­mer biotechs — which set its sights on Cha­gas — isn’t the one ben­e­fit­ing from the mar­ket­ing OK. And Shkre­li’s suc­ces­sors say they now have to switch up their game plan af­ter the ri­val group snagged the valu­able pri­or­i­ty re­view vouch­er that came with the first OK, blast­ing their share price.

The non­prof­it drug de­vel­op­ment or­ga­ni­za­tion Drugs for Ne­glect­ed Dis­eases ini­tia­tive (DNDi), along with the phar­ma­ceu­ti­cal com­pa­ny Chemo Group and the non­prof­it foun­da­tion Mun­do Sano set out a year ago to reg­is­ter the drug in ar­eas where its need­ed, in­clud­ing the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER